CStone Pharmaceuticals (HKG:2616) received ethics approval to begin clinical trials of its core candidate CS5007 in Australia, according to a Friday filing with the Hong Kong bourse.
The firm plans to enroll 310 patients in China and Australia to study the cancer treatment's effects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.